The studies thus far have demonstrated that tumor-intrinsic adenosine metabolism adversely affects CD8+ T cell function; therefore, it is not surprising that these metabolic alterations also contribute to anti-PD-1/PD-L1 resistance. This evidence concerns the gene CD8A and neoplasm.